Company Monitoring Page for Eli-Lilly

latest headlines for company on cafepharma

FDA says no evidence yet linking weight loss drugs to suicidal thoughts
Reuters
Thu, 01/11/24 - 11:35 am
Tags:
Novo Nordisk, Eli Lilly, weight loss, GLP-1 agonist, FDA
JPM24: ‘Diabesity’ duopoly between Novo, Lilly takes center stage
Medical Marketing and Media
Thu, 01/11/24 - 11:18 am
Tags:
JPMHC 2024, obesity, diabetes, diabesity, Novo Nordisk, Eli Lilly
Zepbound shortage could be around the corner
Beckers Hospital Review
Tue, 01/9/24 - 10:05 pm
Tags:
Eli Lilly, Zepbound, obesity, drug shortages, David Ricks, Pharma CEOs
Alphabet’s Isomorphic stacks two new deals with Lilly, Novartis worth nearly $3B ahead of JPM
Fierce Biotech
Sun, 01/7/24 - 04:19 pm
Tags:
Alphabet, Isomorphic, Eli Lilly, Novartis
Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference
Reuters
Fri, 01/5/24 - 11:25 am
Tags:
M&A, JPMHC 2024, AbbVie, AstraZeneca, Bristol Myers Squibb, Carmot Therapeutics, Eli Lilly
Novo Nordisk, Eli Lilly's weight-loss drugs under FDA scrutiny for suicidal thoughts, hair loss
Fierce Pharma
Thu, 01/4/24 - 11:53 am
Tags:
Novo Nordisk, Eli Lilly, weightloss, side effects, Ozempic, Wegovy, Zepbound
Lilly launches website, home delivery option for weight-loss drugs
Reuters
Thu, 01/4/24 - 10:07 am
Tags:
Eli Lilly, obesity, Zepbound
Eli Lilly concludes POINT Biopharma acquisition for $1.4bn
Pharmaceutical Business Review
Sun, 12/31/23 - 11:40 am
Tags:
Eli Lilly, Point Biopharma, M&A, radiopharmaceuticals
Obesity drugs’ next tests, and rising threats: 3 chronic disease stories to watch
Stat
Thu, 12/21/23 - 09:52 am
Tags:
obesity, climate change, Wegovy, Zepbound, Novo Nordisk, Eli Lilly, liver disease
Lilly tames Fauna to go on the prowl for obesity targets in $494M deal
Fierce Biotech
Thu, 12/21/23 - 09:37 am
Tags:
Eli Lilly, Zepbound, obesity, Fauna Bio
Organon pays $50M to pick up rights to pair of Eli Lilly migraine meds in Europe
Fierce Pharma
Mon, 12/18/23 - 10:16 pm
Tags:
Organon, Eli Lilly, migraines, Europe
Point and Lantheus’s Radioligand Drug Shows Effectiveness, but Not Enough for Wall Street
BioSpace
Mon, 12/18/23 - 10:14 pm
Tags:
Point Biopharma, Lantheus Holdings, radioligands, prostate cancer, Eli Lilly
Obesity drug Mounjaro to surpass Ozempic with $27 billion sales in 2029
Biopharma Reporter
Mon, 12/18/23 - 11:37 am
Tags:
Eli Lilly, Novo Nordisk, obesity, weight loss, Ozempic, Mounjaro
Where Will Eli Lilly Be in 5 Years?
Motley Fool
Fri, 12/15/23 - 09:42 am
Tags:
Eli Lilly, Zepbound
Lilly Stock Slips as Patients Regain Weight After Stopping Zepbound
BioSpace
Mon, 12/11/23 - 10:58 pm
Tags:
Eli Lilly, weight loss, Zepbound, GLP-1 agonist
Could Eli Lilly Beat Novo Nordisk in the Billion-Dollar Weight Loss Market?
Motley Fool
Fri, 12/8/23 - 09:56 am
Tags:
Eli Lilly, Novo Nordisk, weight loss, Wegovy, Zepbound
Eli Lilly’s latest $1.4 billion deal might come unglued
Stat
Thu, 12/7/23 - 11:15 pm
Tags:
Eli Lilly, Point Biopharma, M&A
Trial finds Lilly’s Olumiant could treat type 1 diabetes
Pharmaphorum
Thu, 12/7/23 - 11:00 am
Tags:
Eli Lilly, olumiant, type 1 diabetes
Eli Lilly's obesity drug now available in U.S. pharmacies
Reuters
Tue, 12/5/23 - 09:53 am
Tags:
Eli Lilly, obesity, Zepbound, pharmacies
Lilly Wins Second Accelerated Approval for Reversible BTK Inhibitor
BioSpace
Mon, 12/4/23 - 09:41 am
Tags:
Eli Lilly, FDA, Jaypirca, CLL, small lymphocytic leukemia, Btk inhibitors

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.